Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes
1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events ...
Tag: types 2 diabetes
#VisualAbstract: Weekly insulin icodec is more effective than daily basal insulin at reducing HbA1c
1. In this randomized controlled trial, insulin icodec demonstrated superior HbA1c reduction as compared to once-daily basal insulin analogs in ...
